| Literature DB >> 30066054 |
Dagfinn Aune1,2,3, Yahya Mahamat-Saleh4, Teresa Norat5, Elio Riboli6.
Abstract
We conducted a systematic review and meta-analysis to clarify the association between adiposity, diabetes, and physical activity and the risk of kidney stones. PubMed and Embase were searched up to April 22nd 2018 for relevant studies. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random effects models. Thirteen cohort studies were included. The summary relative risk was 1.21 (95% CI 1.12-1.30, I2 = 76%, n = 8) per 5 unit increment in BMI, 1.16 (95% CI 1.12-1.19, I2 = 0%, n = 5) per 10 cm increase in waist circumference, 1.06 (95% CI 1.04-1.08, I2 = 67%, n = 3) per 5 kg increase in weight and 1.12 (95% CI 1.06-1.18, I2 = 86%, n = 3) per 5 kg of weight gain. The summary RR was 1.16 (95% CI 1.03-1.31, I2 = 51%, n = 10) for participants with diabetes compared to participants without diabetes, and 0.93 (95% CI 0.78-1.10, I2 = 80%, n = 4) for high vs. low physical activity. These results suggest a positive association between adiposity and diabetes and the risk of kidney stones, but no association with physical activity.Entities:
Keywords: Body mass index; Cohort studies; Diabetes; Kidney stones; Meta-analysis; Physical activity; Systematic review; Waist circumference; Waist-to-hip ratio
Mesh:
Year: 2018 PMID: 30066054 PMCID: PMC6208979 DOI: 10.1007/s10654-018-0426-4
Source DB: PubMed Journal: Eur J Epidemiol ISSN: 0393-2990 Impact factor: 8.082
Subgroup analyses of BMI and kidney stones
| BMI, per 5 kg/m2 | |||||
|---|---|---|---|---|---|
|
| RR (95% CI) |
|
| ||
| All studies | 8 | 1.21 (1.12–1.30) | 76.4 | < 0.0001 | |
| Sex | |||||
| Men | 3 | 1.24 (1.13–1.36) | 0 | 0.64 | 0.72/0.96c |
| Women | 4 | 1.22 (1.05–1.42) | 88.5 | < 0.0001 | |
| Men and women | 1 | 1.09 (0.86–1.37) | |||
| Assessment of weight/height | |||||
| Measured | 5 | 1.11 (1.07–1.16) | 0 | 0.62 | 0.003 |
| Self-reported | 3 | 1.32 (1.23–1.41) | 32.4 | 0.23 | |
| Duration of follow-up | |||||
| < 10 years follow-up | 3 | 1.12 (1.07–1.17) | 0 | 0.91 | 0.14 |
| ≥ 10 years follow-up | 5 | 1.27 (1.14–1.41) | 78.4 | 0.001 | |
| Geographic location | |||||
| Europe | 0 | 0.20 | |||
| America | 4 | 1.26 (1.12–1.41) | 86.9 | < 0.0001 | |
| Asia | 4 | 1.12 (1.05–1.18) | 0 | 0.45 | |
| Number of cases | |||||
| Cases < 500 | 0 | 0.99 | |||
| Cases 500 to < 1000 | 2 | 1.22 (0.91–1.66) | 46.6 | 0.17 | |
| Cases ≥ 1000 | 4 | 1.26 (1.12–1.41) | 86.9 | < 0.0001 | |
| Study quality | |||||
| 0–3 | 0 | 0.36 | |||
| 4–6 | 1 | 1.49 (1.01–2.21) | |||
| 7–9 | 7 | 1.20 (1.11–1.29) | 78.7 | < 0.0001 | |
| Adjustment for confounders | |||||
| Age | |||||
| Yes | 8 | 1.21 (1.12–1.30) | 76.4 | < 0.0001 | NC |
| No | 0 | ||||
| Alcohol | |||||
| Yes | 4 | 1.29 (1.20–1.40) | 45.0 | 0.14 | 0.007 |
| No | 4 | 1.12 (1.07–1.16) | 0 | 0.46 | |
| Smoking | |||||
| Yes | 4 | 1.12 (1.05–1.18) | 0 | 0.45 | 0.20 |
| No | 4 | 1.26 (1.12–1.41) | 86.9 | < 0.0001 | |
| Diabetes | |||||
| Yes | 4 | 1.11 (1.07–1.15) | 0 | 0.93 | 0.002 |
| No | 4 | 1.32 (1.25–1.41) | 10.0 | 0.34 | |
| Thiazide use | |||||
| Yes | 3 | 1.32 (1.23–1.41) | 32.4 | 0.23 | 0.003 |
| No | 5 | 1.11 (1.07–1.16) | 32.4 | 0.23 | |
| Fluids | |||||
| Yes | 3 | 1.32 (1.23–1.41) | 32.4 | 0.23 | 0.003 |
| No | 5 | 1.11 (1.07–1.16) | 0 | 0.62 | |
| Sodium | |||||
| Yes | 4 | 1.29 (1.20–1.40) | 45.0 | 0.14 | 0.007 |
| No | 4 | 1.12 (1.07–1.16) | 0 | 0.46 | |
| Potassium | |||||
| Yes | 6 | 1.22 (1.11–1.33) | 76.2 | 0.001 | 0.69 |
| No | 2 | 1.21 (0.93–1.56) | 53.0 | 0.15 | |
| Animal protein, protein | |||||
| Yes | 5 | 1.23 (1.12–1.35) | 80.1 | < 0.0001 | 0.43 |
| No | 3 | 1.12 (1.04–1.21) | 8.5 | 0.34 | |
| Dietary calcium | |||||
| Yes | 7 | 1.20 (1.11–1.29) | 78.7 | < 0.0001 | 0.36 |
| No | 1 | 1.49 (1.01–2.21) | |||
| Calcium supplements | |||||
| Yes | 3 | 1.12 (1.04–1.21) | 8.5 | 0.34 | 0.003 |
| No | 5 | 1.30 (1.21–1.40) | 32.2 | 0.21 | |
| Physical activity | |||||
| Yes | 5 | 1.11 (1.07–1.16) | 0 | 0.62 | 0.003 |
| No | 3 | 1.32 (1.23–1.41) | 32.4 | 0.23 | |
n denotes the number of studies
aP for heterogeneity within each subgroup
bP for heterogeneity between subgroups
cP for heterogeneity between men and women (excluding men/women combined)
Fig. 1Flow-chart of study selection
Subgroup analyses of diabetes and kidney stones
| Diabetes | |||||
|---|---|---|---|---|---|
|
| RR (95% CI) |
|
| ||
| All studies | 10 | 1.16 (1.03–1.31) | 50.5 | 0.03 | |
| Sex | |||||
| Men | 2 | 0.91 (0.75–1.10) | 0 | 0.34 | 0.24/0.09c |
| Women | 3 | 1.29 (1.08–1.55) | 32.5 | 0.23 | |
| Men and women | 5 | 1.19 (1.02–1.38) | 33.6 | 0.20 | |
| Duration of follow-up | |||||
| < 10 years follow-up | 5 | 1.12 (1.01–1.24) | 0 | 0.53 | 0.41 |
| ≥ 10 years follow-up | 5 | 1.25 (0.98–1.61) | 71.2 | 0.008 | |
| Geographic location | |||||
| Europe | 2 | 1.23 (1.06–1.44) | 0 | 0.71 | 0.15 |
| America | 5 | 1.25 (0.98–1.59) | 71.9 | 0.007 | |
| Asia | 3 | 1.04 (0.90–1.20) | 0 | 0.80 | |
| Number of cases | |||||
| Cases < 500 | 0 | 0.87 | |||
| Cases 500 to < 1000 | 4 | 1.18 (0.94–1.48) | 43.8 | 0.15 | |
| Cases ≥ 1000 | 6 | 1.15 (0.99–1.35) | 60.6 | 0.03 | |
| Study quality | |||||
| 0–3 | 0 | NC | |||
| 4–6 | 2 | 1.04 (0.87–1.24) | 0 | 0.50 | |
| 7–9 | 8 | 1.20 (1.03–1.38) | 56.0 | 0.03 | |
| Adjustment for confounders | |||||
| Age | |||||
| Yes | 10 | 1.16 (1.03–1.31) | 50.5 | 0.03 | NC |
| No | 0 | ||||
| Alcohol | |||||
| Yes | 3 | 1.19 (0.84–1.69) | 79.7 | 0.007 | 0.80 |
| No | 7 | 1.14 (1.02–1.27) | 24.4 | 0.24 | |
| Smoking | |||||
| Yes | 3 | 1.06 (0.92–1.22) | 0 | 0.74 | 0.38 |
| No | 7 | 1.22 (1.02–1.45) | 60.8 | 0.02 | |
| BMI, adiposity | |||||
| Yes | 5 | 1.14 (1.03–1.26) | 0 | 0.61 | 0.54 |
| No | 5 | 1.24 (0.96–1.59) | 73.5 | 0.005 | |
| Thiazide use | |||||
| Yes | 3 | 1.19 (0.84–1.69) | 79.7 | 0.007 | 0.80 |
| No | 7 | 1.14 (1.02–1.27) | 24.4 | 0.24 | |
| Fluids | |||||
| Yes | 3 | 1.19 (0.84–1.69) | 79.7 | 0.007 | 0.80 |
| No | 7 | 1.14 (1.02–1.27) | 24.4 | 0.24 | |
| Sodium | |||||
| Yes | 3 | 1.19 (0.84–1.69) | 79.7 | 0.007 | 0.80 |
| No | 7 | 1.14 (1.02–1.27) | 24.4 | 0.24 | |
| Potassium | |||||
| Yes | 5 | 1.13 (0.92–1.38) | 66.4 | 0.02 | 0.69 |
| No | 5 | 1.19 (1.02–1.38) | 33.6 | 0.20 | |
| Animal protein | |||||
| Yes | 5 | 1.13 (0.92–1.38) | 66.4 | 0.02 | 0.69 |
| No | 5 | 1.19 (1.02–1.38) | 33.6 | 0.20 | |
| Dietary calcium | |||||
| Yes | 5 | 1.13 (0.92–1.38) | 66.4 | 0.02 | 0.69 |
| No | 5 | 1.19 (1.02–1.38) | 33.6 | 0.20 | |
| Calcium supplements | |||||
| Yes | 5 | 1.13 (0.92–1.38) | 66.4 | 0.02 | 0.69 |
| No | 5 | 1.19 (1.02–1.38) | 33.6 | 0.20 | |
| Physical activity | |||||
| Yes | 2 | 1.04 (0.87–1.24) | 0 | 0.50 | 0.43 |
| No | 8 | 1.20 (1.03–1.38) | 56.0 | 0.03 | |
n denotes the number of studies
aP for heterogeneity within each subgroup
bP for heterogeneity between subgroups
cP for heterogeneity between men and women (excluding men/women combined)
Fig. 2Body mass index and risk of kidney stones
Fig. 3Waist circumference and risk of kidney stones
Fig. 4Weight and risk of kidney stones
Fig. 5Weight gain and risk of kidney stones
Fig. 6Diabetes mellitus and physical activity and risk of kidney stones
Fig. 7Physical activity and risk of kidney stones